Arcus Biosciences recently announced initial overall survival results from the Phase 2 EDGE-Gastric study, showing a median overall survival of 26.7 months for domvanalimab plus zimberelimab with chemotherapy in advanced gastric,

We are now witnessing the start of what might be seen as Phase 2 of Trump’s efforts to eradicate political opposition. Phase 1 has centered on silencing criticism. It has featured retribution toward people Trump deemed personal “enemies” — not just ...

The novel serotonin norepinephrine reuptake inhibitor (SNRI) ammoxetine may effectively treat major depressive disorder (MDD) while avoiding some side effects common to other antidepressants, new phase 2 data suggested. Investigators found that ...

We are now witnessing the start of what might be seen as Phase 2 of Trump’s efforts to eradicate political opposition. Phase 1 has centered on silencing criticism. It has featured retribution toward people Trump deemed personal “enemies” — not just ...

SAN DIEGO, Sept. 16, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present new data from the Phase 2 SAVITRI study of osavampator in adults with major depressive disorder at Psych Congress 2025, taking place ...